• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
By KEVIN CURRAN Nov 19, 2018 | 12:32 PM EST
Stocks quotes in this article: PFE, MRK, GSK, JNJ, BMS, RHHBY

Pfizer's  (PFE)  cancer drugs could be key to unlocking value for longer term shareholders.

Shares of the pharma have begun Monday's trading slightly positive despite pressure on the stock motivated by drug pricing concerns.

Oncology drugs may be the key to continuing the positive trend, according to analysts

"PFE's oncology assets will make up 13% of its total 2018 sales, according to FactSet, and they will accelerate PFE's sales growth for the foreseeable future, but these drugs are underappreciated," Cantor Fitzgerald analyst Louise Chen wrote on Sunday.

She set a "Buy" rating and a $53 12-month price target for the stock.

Market Opportunity

The cancer drug market is expected to accelerate quickly in the coming years, growing from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020, according to Allied Market Research.

The growth in the oncology drug market coupled with the high regulatory and research cost barriers associated with cancer drug manufacturing sets up a large market that only companies like Merck (MRK) , Pfizer, and GlaxoSmithKline (GSK) can attack effectively.

Chen noted that there are further opportunities for pharma giants like Pfizer to move in on even emerging markets, as they offer lower regulatory barriers.

"Asia-Pacific and LAMEA (Latin America, Middle East, Africa) are promising regions for conducting clinical trials due a large population base and the low cost of clinical trials as compared to North America and Europe," Chen wrote. "[Both regions] offer lucrative opportunities for the expansion of the oncology/cancer drugs market."

Testing Troubles

To be sure, the burgeoning segment is not without hiccups.

Bavencio, a joint venture alongside Merck, failed to show efficacy in treating ovarian cancer in test results released Monday morning, suggesting further retooling of the potentially profitable drug is necessary.

The failure of this drug trial presents the possible problem ahead if pipelines do not meet the growing global demand for oncology products.

Further, the company will face significant competition across markets.

According to Statista, Johnson & Johnson (JNJ) , Bristol Myers Squibb (BMS) , Merck, and Roche Holdings (RHHBY) all currently hold higher revenue cancer drugs than Pfizer.

Bull Case Builds for Long Term

The company may have run into a problem with one drug on Monday, but it is hardly the only drug in the pipeline.

CEO Ian Read noted the approval of two new drugs in October and two more to come before the end of the year.

Chen noted the sales potential of these major drugs, given the success of the company's Ibrance cancer treatment offering, to be significantly undervalued.

Further, the company sees a plethora of releases upcoming into the five years.

"We continue to see the potential for approximately 25 to 30 approvals through 2022, of which up to half have the potential to be blockbusters," Read told analysts during the call, many of which are likely to come from the high profit margin oncology unit given the company's stated focus on the segment.

As such, the oncology unit may be just the opportunity to justify a jump aboard the bandwagon of a perennial top-performer in pharma. 

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Jim Cramer and the AAP team hold a position in Johnson & Johnson for their Action Alerts PLUS Charitable Trust Portfolio . Want to be alerted before Cramer buys or sells JNJ? Learn more now.

TAGS: Drug Approvals | Investing | Markets | Stocks | Pharmaceuticals | Stock of the Day

More from Investing

Rotation Is No Reason to Turn Away from the Markets

James "Rev Shark" DePorre
Jan 21, 2021 4:45 PM EST

Bears may fuss over the routine consolidation combined with rotational action, but here's how I look at the moves.

Jim Cramer: Housing Is Our Bridge

Jim Cramer
Jan 21, 2021 3:59 PM EST

Do not fear the housing sales boom -- this is good news and I'll tell you why.

Cord-Cutting FuboTV and Advertising Platform PubMatic Are Not Buys Here

Bruce Kamich
Jan 21, 2021 2:59 PM EST

Our look at the stocks of both FUBO and PUBM.

Jim Cramer: You Just Won Powerball, Now What?

Jim Cramer
Jan 21, 2021 2:24 PM EST

Remember, you only need to get rich once.

Here's the Beast and Beauty of Investing in Disney Now

Bruce Kamich
Jan 21, 2021 1:54 PM EST

DIS might suffer a pullback in the next several weeks, but longer-term a rally is possible, according to the charts.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • 08:35 AM EST GARY BERMAN

    Thursday Morning Fibocall for 1/21/2021

    SPX (Long-Term View) The 1/20/21 NEW high @ 3859...
  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login